...
首页> 外文期刊>Biochimica et Biophysica Acta. Molecular and cell biology of Lipids >Control of cholesterol biosynthesis, uptake and storage in hepatocytes by Cideb.
【24h】

Control of cholesterol biosynthesis, uptake and storage in hepatocytes by Cideb.

机译:Cideb控制胆固醇在肝细胞中的生物合成,摄取和储存。

获取原文
获取原文并翻译 | 示例
           

摘要

Cideb, a member of CIDE family proteins, has emerged as an important regulator in the development of obesity and diabetes by controlling fatty acid synthesis and VLDL secretion in hepatocytes. Here, we investigated the role of Cideb in cholesterol biosynthesis, uptake and storage in the liver by using Cideb-null mice as a model system. Cideb-null mice and wild-type mice were treated with normal diet (ND) or high cholesterol diet (HCD) for one month. The metabolic parameters of cholesterol metabolism and expression profiles of genes in cholesterol biosynthesis and storage were measured. Cideb-null mice had lower levels of plasma cholesterol and LDL when fed with both ND and HCD and increased rate of cholesterol absorption. Furthermore, the liver of Cideb-null mice has lower rates of cholesterol biosynthesis and reduced expression levels of sterol response element-binding protein (SREBP) cleavage-activation protein (SCAP), and lower levels of nuclear form of SREBP2 and its downstream target genes in cholesterol biosynthesis pathway under a normal diet treatment. On the contrary, hepatic cholesterol biosynthesis rate between wild-type and Cideb-null mice was similar after high cholesterol diet treatment. Interestingly, hepatic cholesterol storage in the liver of Cideb-null mice was significantly increased due to its increased LDL receptor (LDLR) and acyl-CoA cholesterol acyltransferase (ACAT) expression. Finally, we observed drastically reduced cholesterol levels in the heart of Cideb-null mice fed with a high cholesterol diet. Overall, our data suggest that Cideb is a novel regulator in controlling cholesterol homeostasis in the liver. Therefore, Cideb could serve as an important therapeutical target for the treatment of atherosclerosis and cardiovascular diseases.
机译:Cideb是CIDE家族蛋白的成员,通过控制肝细胞中的脂肪酸合成和VLDL分泌,已成为肥胖症和糖尿病发展中的重要调节剂。在这里,我们通过使用无Cideb的小鼠作为模型系统研究了Cideb在胆固醇生物合成,肝脏吸收和储存中的作用。使用正常饮食(ND)或高胆固醇饮食(HCD)治疗Cideb无效小鼠和野生型小鼠一个月。测量了胆固醇代谢的代谢参数以及胆固醇生物合成和储存中基因的表达谱。饲喂ND和HCD的Cideb-null小鼠血浆胆固醇和LDL水平较低,并且胆固醇吸收率较高。此外,Cideb无效小鼠的肝脏具有较低的胆固醇生物合成速率,并降低了固醇反应元件结合蛋白(SREBP)裂解激活蛋白(SCAP)的表达水平,并且具有较低的核形式SREBP2及其下游靶基因正常饮食治疗下胆固醇的生物合成途径相反,高胆固醇饮食治疗后,野生型和Cideb-null小鼠之间的肝胆固醇生物合成速率相似。有趣的是,由于Cideb-null小鼠肝脏中LDL受体(LDLR)和酰基CoA胆固醇酰基转移酶(ACAT)的表达增加,其肝脏胆固醇的存储量显着增加。最后,我们观察到高胆固醇饮食喂养的Cideb无效小鼠心脏的胆固醇水平大大降低。总体而言,我们的数据表明Cideb是控制肝脏胆固醇稳态的新型调节剂。因此,Cideb可以作为治疗动脉粥样硬化和心血管疾病的重要治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号